Trials / Completed
CompletedNCT02387983
Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)
Pharmacokinetics and Safety of Solid Oral Posaconazole (MK-5592, POS) in Chinese Subjects at High Risk for Invasive Fungal Infections
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the pharmacokinetics and safety of oral posaconazole tablets in Chinese participants at high risk for invasive fungal infections. Neutropenic participants undergoing chemotherapy for acute myelogenous leukemia or myelodysplastic syndromes will be enrolled in the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Posaconazole | Posaconazole 300 mg solid oral tablet |
Timeline
- Start date
- 2015-05-06
- Primary completion
- 2016-05-02
- Completion
- 2016-05-02
- First posted
- 2015-03-13
- Last updated
- 2018-10-09
- Results posted
- 2017-07-14
Source: ClinicalTrials.gov record NCT02387983. Inclusion in this directory is not an endorsement.